Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, has published its 2025 Corporate Responsibility Report, outlining its commitment to improving global health through six key pillars. Highlights include a new greenhouse gas emissions reduction framework, expanded patient support initiatives, and increased philanthropic investments aimed at underserved communities.

• 01Alnylam established a Scope 1 and Scope 2 greenhouse gas emissions reduction framework targeting 2030, validated by a third-party assessment.
• 02The company launched a Patient Advisory Council and expanded its Case Management and Access & Reimbursement teams to enhance patient support.
• 03Alnylam committed $2 million over two years to support frontline Care Navigators in Boston through partnerships with local health institutions.
• 04The report includes case studies demonstrating the strategic value of investments in AI, manufacturing, and employee resource networks.
• 05Yvonne Greenstreet, M.D., emphasized the importance of corporate responsibility in delivering life-changing medicines.

The report's initiatives, particularly the support for frontline Care Navigators, aim to improve healthcare access for underserved communities in Boston.